Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Wave Life Sciences ( (WVE) ) is now available.
On August 5, 2025, Wave Life Sciences Ltd. held its Annual General Meeting where shareholders approved several key proposals, including an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 8,000,000. The meeting also saw the re-election of nine directors, the re-appointment of KPMG LLP as the company’s auditor, and approval of compensation plans for non-employee directors and executive officers, reflecting strong shareholder support for the company’s strategic initiatives.
The most recent analyst rating on (WVE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.
Spark’s Take on WVE Stock
According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.
Wave Life Sciences’ overall stock score is primarily impacted by significant financial challenges, including declining revenues and persistent losses. However, positive technical indicators and promising advancements in clinical programs provide some optimism. The company’s strong cash position and favorable analyst sentiment further contribute positively, but financial instability remains a major concern.
To see Spark’s full report on WVE stock, click here.
More about Wave Life Sciences
Average Trading Volume: 1,330,698
Technical Sentiment Signal: Buy
Current Market Cap: $1.29B
For an in-depth examination of WVE stock, go to TipRanks’ Overview page.